Merck Sharp & Dohme LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$164Mgeneral payments (2019-2025)
$1.1Mresearch payments (2019-2025)
283,214clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Verquvo $12M associated (2023-2025)
- Keytruda $11M associated (2023-2025)
- Winrevair $3.2M associated (2023-2025)
- Gardasil 9 $2.7M associated (2023-2025)
- Lynparza $1.8M associated (2023-2025)
- Vaxneuvance $1.7M associated (2023-2025)
- Capvaxive $1.7M associated (2023-2025)
- Bridion $1.5M associated (2023-2025)
- Welireg $1.2M associated (2023-2025)
- Vaxelis $1.1M associated (2023-2025)
- Zerbaxa $1.0M associated (2023-2025)
- Gardasil $903K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Marc Sabatine | Boston, MA | Cardiovascular Disease | $3,557,156.92 |
| Pan Zheng | Washington, DC | Clinical Pathology/Laboratory Medicine | $2,442,157.70 |
| Rajan Agarwal | Abington, PA | Diagnostic Radiology | $2,064,458.60 |
| Craig Thompson | New York, NY | Medical Oncology | $1,990,923.53 |
| Stephan Anderson | Boston, MA | Diagnostic Radiology | $1,426,335.00 |
| Ashraf Thabet | Boston, MA | Diagnostic Radiology | $1,289,505.00 |
| Nisha Sainani | Boston, MA | Body Imaging | $1,219,155.50 |
| Gregg Miller | Boston, MA | Diagnostic Radiology | $1,204,950.00 |
| Judith Wolf | Philadelphia, PA | Infectious Disease | $1,099,638.21 |
| William Corse | Doylestown, PA | Diagnostic Radiology | $1,090,129.55 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.